Syngene International Limited, India's leading contract research, development and manufacturing organization (CDMO) has reported steady fourth-quarter and full-year results for FY26, driven by continued investments in biologics and emerging modalities.

 

For Q4 FY26, revenue from operations rose 2% year-on-year to Rs 1,037 Cr and was up 13% sequentially. Operating EBITDA margin stood at 29%, while profit after tax (before exceptional items) was Rs 153 Cr. Reported PAT after exceptional items for the quarter was Rs 148 Cr.

 

For the full year FY26, revenue from operations increased 3% to Rs 3,739 Cr, with an operating EBITDA margin of 25%. Profit after tax (before exceptional items) stood at Rs 380 Cr, while reported PAT after exceptional items was Rs 317 Cr. The company generated net cash of Rs 521 Cr during the year.

 

Kiran Mazumdar-Shaw, Executive Chairperson, said, “I am pleased to take on the role of Executive Chairperson at Syngene at a pivotal moment in its growth journey. While biotech funding remains discerning and largely concentrated on late-stage assets, Syngene’s diversified end-to-end business model—from discovery and development to manufacturing—gives us both resilience and strategic agility in navigating these market realities. We are also focused on building new business lines, strengthening our differentiated service offerings, and investing in AI and digital capabilities that will enhance speed, productivity, and value creation for our clients.”

 

Peter Bains, Managing Director and CEO, said, “Syngene’s full-year revenue from operations grew 3%, and with an EBITDA margin of 25%, performance was in line with our revised full-year guidance. The overall numbers reflect the specific impact from a single large-molecule biologics client, with the underlying business showing steady momentum. During the year, we continued to invest in new capabilities and emerging modalities such as peptides and ADCs, further strengthening our integrated offering and positioning us for long-term growth.

 

Deepak Jain, Chief Financial Officer, added, “Q4 reported growth at 2% and 13% sequentially reflects the ongoing product impact in our largest biologics customer, resulting in full year growth of 3%. Operating EBITDA margin at 25% for the year reflects this impact and additional operating costs as we bring the new biologics manufacturing facility in India into operations. We generated Rs. 521 Cr of cash during the year, post capex investment, strengthening our balance sheet.”

 

The Board has recommended a final dividend of Rs 1.25 per share for FY26, subject to shareholder approval. Key leadership changes include the transition of Kiran Mazumdar-Shaw to Executive Chairperson, and the appointment of Siddharth Mittal as Managing Director and CEO effective July 1, 2026.